

## Contents

Preface XIII

List of Contributors XV

### Part I Stem Cell Biology

- 1 Clinical Potentials of Stem Cells: Hype or Hope?** 3  
*Anthony D. Ho and Wolfgang Wagner*
- 1.1 Introduction 3
- 1.2 What are Stem Cells? 3
- 1.3 Stem Cells and Regeneration 4
- 1.4 Adult and Embryonic Stem Cells 6
- 1.5 In the Beginning was the Hematopoietic Stem Cell 7
- 1.6 Trans-Differentiation of ASCs 8
- 1.7 The Plasticity of ASCs: All Hype and no Hope? 9
- 1.8 The Battle of Two Cultures: ESCs versus ASCs 10
- 1.9 The Challenges for Stem Cell Technology 11
- 1.10 Regulation of Self-Renewal versus Differentiation,  
 Asymmetric Divisions 12
- 1.11 Genotype and Expression Profiles of Primitive HSCs 14
- 1.12 Maintaining Stemness: Interactions between HSCs  
 and the Cellular Microenvironment 15
- 1.13 Mesenchymal Stem Cells 16
- 1.14 Preliminary Clinical Studies 18
- 1.15 Concluding Remarks and Future Perspectives 19
- 2 Alteration of Hematopoietic Stem Cell Fates by  
 Chromatin-Modifying Agents** 27  
*Nadim Mahmud, Mohammed Milhem, Hiroto Araki, and Ronald Hoffman*
- 2.1 Introduction 27
- 2.2 Cytotoxicity/Antitumor Activity versus Hypomethylating Effects  
 of 5-Azacytidine and its Analogues 29

2.3	Treating HSC with 5azaD/TSA can Alter their Fate	30
2.4	Are the Effects of 5azaD/TSA Due to Cytotoxicity?	32
2.5	Treating HSC with Valproic Acid	33
2.6	<i>Ex-vivo</i> Expansion of HSC Using Chromatin-Modifying Agents	33
2.7	Reactivation of Gene Expression by Treating Cells with Chromatin-Modifying Agents	34
2.8	Alteration of Nonhematopoietic Fate by Chromatin-Modifying Agents	35
2.9	Safety/Toxicity of Treating Cells with Chromatin-Modifying Agents	36
2.10	Conclusion	37

**3 Increasing Impact of Micro RNAs in Stem Cell Biology and Medicine** 43

*Peter Wernet*

3.1	Introduction	43
3.2	Biogenesis of miRNAs	44
3.3	Action Modes of miRNAs	46
3.4	Potential Function Modes of miRNAs	48
3.5	Conclusions	50

**Part II Standardization and Quality Assurance of Stem Cell Preparations**

**4 Novel Strategies for the Mobilization of Hematopoietic Stem Cells** 57

*Stefan Fruehauf, Timon Seeger, and Julian Topaly*

4.1	Physiology of Blood Stem Cell Mobilization	57
4.1.1	Stromal-Derived Factor-1 Alpha (SDF-1 $\alpha$ )/CXCR4 Pathway	58
4.2	Innovative Agents for PBPC Mobilization	63
4.2.1	AMD-3100	63
4.2.2	CTCE0021 and CTCE0214	65
4.2.3	C3aR Antagonist SB 290157	66
4.2.4	GRO $\beta$ T (CXCL2 $\Delta$ 4)	66

**5 Pluripotent Stem Cells from Umbilical Cord Blood** 73

*Gesine Kögler and Peter Wernet*

5.1	Biological Advantages of Cord Blood as a Stem Cell Resource	73
5.2	The Generation and Expansion of Pluripotent Cells (USSC) from Cord Blood	74
5.2.1	Generation and Expansion of USSC from Fresh CB	74
5.2.2	Generation and Expansion of USSC from Cryoconserved CB	76
5.2.3	Immunophenotype of USSC Obtained from Fresh and Cryopreserved CB Specimens	77
5.2.4	Expansion of USSC	77

5.2.5	The Differentiation Potential of USSC	77
5.2.5.1	<i>In-vitro</i> and <i>In-vivo</i> Differentiation of USSC into Mesenchymal Cell Lineages	77
5.2.5.2	Differentiation of USSC into Neural Cells <i>In Vitro</i> and <i>In Vivo</i>	80
5.2.5.3	Application of USSC to the Fetal Sheep Xenograft Model to Study <i>In-vivo</i> Hematopoiesis	80
5.2.5.4	<i>In-vivo</i> Differentiation of USSC into Myocardial Cells and Purkinje Fibers in the Preimmune Fetal Sheep	81
5.2.5.5	<i>In-vivo</i> Differentiation of USSC into Hepatic Cells in the Preimmune Fetal Sheep	81
5.2.6	Cytokine Production and Hematopoiesis Supporting Activity of CB-Derived Unrestricted Somatic Stem Cells	82
5.2.6.1	Rationale for Application of USSC to Support Hematopoiesis	82
5.2.6.2	Qualitative and Quantitative Assessment of Cytokines Produced by USSC or Bone Marrow MSC	83
5.2.6.3	Hematopoiesis Supporting Stromal Activity of USSC in Comparison to BM MSC	84
5.3	Other Multipotent Nonhematopoietic Stem Cells: Mesenchymal Cells in CB and CB Tissue	85
5.4	Conclusion: Future Efforts Towards the Regenerative Capacity of CB Nonhematopoietic Cells	85
<b>6</b>	<b>Good Manufacturing Practices: Clinical-Scale Production of Mesenchymal Stem Cells</b>	91
	<i>Luc Sensebé, Philippe Bourin, and Luc Douay</i>	
6.1	Introduction	91
6.2	Prerequisites for the Clinical-Scale Production of MSCs	92
6.2.1	Starting Material	92
6.2.1.1	Are there Alternative Sources of MSCs?	93
6.2.2	Cell Plating Density	94
6.2.3	Number of Passages	95
6.2.4	Medium	95
6.2.5	Culture with Biomaterials	96
6.3	Clinical-Scale Production: the French Experience	97
6.3.1	Culture Conditions	97
6.3.2	Devices for MSC Culture	98
6.4	QA and QC	99
6.4.1	French Experimental System GESAQ	99
6.4.2	Quality Controls	100
6.4.2.1	Control of the Harvested Graft	100
6.4.2.2	Controls During Culture	102
6.4.2.3	Controls During Release of the Graft	102
6.5	Future Prospects	102

<b>7</b>	<b>The Clonal Activity of Marked Hematopoietic Stem Cells</b>	<b>107</b>
	<i>Jingqiong Hu, Manfred Schmidt, Annette Deichmann, Hanno Glimm, and Christof von Kalle</i>	
7.1	Introduction	107
7.2	Characterization of <i>In-vivo</i> Clonal Activity of HSCs by Genetic Marking	107
7.3	Retroviral Integration Site Analysis	108
7.4	Clonality Analysis in Animal Model and Human Gene Therapy Trials	109
7.4.1	Clonal Activity of Marked HSCs in Mouse Models	109
7.4.2	Clonal Activity of Marked HSCs in Non-Human Primate Models	110
7.4.3	Clonal Activity of Marked HSCs in Human Gene Therapy Clinical Trials	110
7.4.3.1	Clonality Analysis in ADA-SCID Gene Therapy Clinical Trial	110
7.4.3.2	Clonality Analysis in SCID-X1 Gene Therapy Clinical Trial	111
7.4.3.3	LMO2 Insertion Leads to Malignant Expansion of Marked HSCs	112
7.5	Interaction of Retroviral Integration Site and Transgene Expression with Clonal Activity of the Respective HSC	113
7.5.1	Impact of Transgene Expression on Clonal Activity of Marked HSCs	114
7.6	Clinical Interventions Affect the Clonal Activity of Marked HSCs	114
7.7	Perspectives	115

### Part III On the Threshold to Clinical Applications

<b>8</b>	<b>A Large Animal Non-Injury Model for Study of Human Stem Cell Plasticity</b>	<b>121</b>
	<i>Graça Almeida-Porada, Christopher D. Porada, and Esmail D. Zanjani</i>	
8.1	Introduction	121
8.2	The Uniqueness of the Fetal Sheep Model	123
8.3	Differentiative Potential of Human Cells in the Fetal Sheep Model	126
<b>9</b>	<b>Developmental Potential of Somatic Stem Cells Following Injection into Murine Blastocysts</b>	<b>133</b>
	<i>Michael Dürr, Friedrich Harder, and Albrecht M. Müller</i>	
9.1	Introduction	133
9.2	Neurosphere Cells Generate Erythroid-Like Cells Following Injection into Early Embryos	134
9.3	Hematopoietic Chimerism by Human Cord Blood-Derived HSCs	138
9.4	Injection of Leukemic Cells into Blastocysts	138
9.5	Discussion	140

<b>10</b>	<b>Testing the Limits: The Potential of MAPC in Animal Models</b>	<b>147</b>
	<i>Felipe Prósper and Catherine M. Verfaillie</i>	
10.1	Introduction	147
10.2	Characterization of MAPCs	148
10.2.1	Phenotype of MAPCs	148
10.2.2	Proliferative Capacity of MAPCs and Culture Conditions	148
10.3	<i>In-Vitro</i> Differentiation Potential of MAPCs	150
10.4	<i>In-Vivo</i> Differentiation Potential of MAPCs	150
10.5	Mechanisms Underlying the Phenomenon of MAPCs	152
10.6	Conclusion	154
<b>11</b>	<b>Mesenchymal Stem Cells as Vehicles for Genetic Targeting of Tumors</b>	<b>157</b>
	<i>Frank Marini, Brett Hall, Jennifer Dembinski, Matus Studeny, A. Kate Sasser, and Michael Andreeff</i>	
11.1	Introduction	157
11.2	The Tumor Stroma and its Components	158
11.3	The Role of Tumor–Stroma Interactions in Tumor Progression	161
11.4	The Similarity of MSC Tumor Tropism to Wound Healing	162
11.5	The Rationale for using MSCs as Cellular Delivery Vehicles	162
11.5.1	Recent Studies of MSC as Cellular Vehicles	164
11.6	The Challenges in Developing MSC-Based Delivery Strategies	167
11.7	Conclusions	167

## Part IV Clinical Trials

<b>12</b>	<b>Endothelial Progenitor Cells for Cardiac Regeneration</b>	<b>179</b>
	<i>Ulrich Fischer-Rasokat and Stefanie Dimmeler</i>	
12.1	Characterization of Endothelial Progenitor Cells	179
12.2	Functions of EPCs to Improve Cardiac Function	181
12.2.1	Improvement of Neovascularization	182
12.2.2	Paracrine Effects	183
12.2.3	Differentiation and/or Fusion	183
12.3	Mechanisms of Homing	184
12.3.1	Adhesion	184
12.3.2	Chemotaxis, Migration, and Invasion	186
12.4	Results from Clinical Studies	186
12.4.1	Stem/Progenitor Cell Therapy in Patients after Acute Myocardial Infarction	189
12.4.2	Stem/Progenitor Cell Therapy in Patients with Chronic Ischemic Heart Failure	190

<b>13</b>	<b>Stem Cells and Bypass Grafting for Myocardial and Vascular Regeneration</b> 197 <i>Christof Stamm, Dirk Strunk, and Gustav Steinhoff</i>
13.1	Introduction 197
13.2	Coronary Artery Disease 198
13.2.1	Myocardial Ischemia 198
13.3	Indications for CABG Surgery 199
13.3.1	Outcome of CABG Surgery 200
13.3.2	Technique of CABG Surgery 201
13.4	The Rationale for Cell Therapy in CABG Patients 202
13.5	The Role of Bone Marrow Cells 202
13.5.1	Bone Marrow Cells and Angiogenesis 202
13.5.2	Bone Marrow Cells and Myogenesis 205
13.6	Combination of (Stem) Cell Treatment with CABG Surgery 207
13.6.1	Skeletal Myoblasts 207
13.6.2	Bone Marrow Mononuclear Cells 209
13.6.3	Bone Marrow Stem Cells 210
13.6.3.1	Cell Preparation 212
13.6.3.2	Surgery 214
13.6.3.3	Preliminary Results 214
13.7	Outlook 216
<b>14</b>	<b>Adoptive Immunotherapy: Guidelines and Clinical Practice</b> 221 <i>Hans-Jochem Kolb, Christoph Schmid, Iris Bigalke, Raymund Buhmann, Belinda Simoes, Ting Yang, Johanna Tischer, Michael Stanglmaier, Horst Lindhofer, Christine Falk, and Georg Ledderose</i>
14.1	Introduction 221
14.2	Animal Experiments 222
14.3	The First Clinical Results in CML 222
14.4	The EBMT Study 222
14.5	The Graft-versus-Leukemia Effect 224
14.6	Cytokines 225
14.7	Bispecific Antibodies 227
14.8	NK and NK-T Cells and HLA-Haploidentical Transplantation 228
14.9	Outlook of Adoptive Immunotherapy in Chimerism 229
<b>15</b>	<b>Immune Escape and Suppression by Human Mesenchymal Stem Cells</b> 233 <i>Katarina Le Blanc and Olle Ringdén</i>
15.1	Introduction 233
15.2	MSCs Escape the Immune System 234
15.3	Immunosuppression by MSCs 235
15.4	MSC in the Clinic 239

<b>16</b>	<b>Stem Cell Transplantation: The Basis for Successful Cellular Immunotherapy</b>	<b>247</b>
	<i>Peter Dreger, Matthias Ritgen, and Anthony D. Ho</i>	
16.1	Introduction	247
16.2	Allogeneic Stem Cell Transplantation in CLL	247
16.3	Graft-versus-Leukemia Effect in CLL	249
16.4	Allo-SCT with Reduced-Intensity Conditioning in CLL	249
16.5	RICT from Unrelated Donors	251
16.6	T-Cell Depletion	252
16.7	Allo-SCT in Follicular Lymphoma	253
16.8	Allo-SCT in Waldenström's Disease	255
16.9	Conclusions and Perspectives	257
	<b>Index</b>	<b>261</b>